British psychedelic drug developer Beckley Psytech has shared topline data from a Phase 2b study of its lead candidate, intranasal 5-MeO-DMT (BPL-003), in treatment-resistant depression (TRD). The results were released this morning by way of a joint announcement with atai Life Sciences, which is set to acquire Beckley following the successful results.The headline finding is that the short-acting…
